At Tocris we welcome all comments and feedback
Your comments are very important to us - to leave feedback please fill in the form below. You may omit your personal contact details if you wish to remain anonymous.
|Company Name / Establishment|
Unfortunately, Tocris Bioscience are no longer able to supply products to customers in your territory. We welcome you to continue signing up for Tocris literature.
We may like to use your comments in our marketing materials. Please tick this box if you are happy for us to do so.
(*) Required Fields
Find multiple products by catalog number
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.